An interventional study of Standard rehabilitation plus cold water hydrotherapy and Standard rehabilitation only in Post-COVID / Long-COVID, POST-Covid 19 and Post COVID Syndrome, sponsored by Schön Klinik Berchtesgadener Land. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-28.
Sponsored by Schön Klinik Berchtesgadener Land · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany — 14 open to participants now, 17 under way, 2 of them phase 3. Post-Acute COVID-19 Syndrome · Germany.
Among the 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany, this one is the 23rd largest by planned enrollment of the 28 interventional ones that give a count, is one of 7 that started in 2025, is one of 20 with no phase, reaches primary completion later than 8 of the 16 other live ones, and was the 35th registered.
606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →14 of the 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany are open now. Recruiting first, the newest first:
University Hospital Schleswig-Holstein · Sites in Germany
Ages 18+
Eggensberger OHG · Sites in Germany
Ages 18+
Max-Planck-Institute of Psychiatry · Sites in Germany
Ages 18–65
Hellenic Institute for the Study of Sepsis · Sites in Germany, Greece, Italy and 1 more country
Ages 18+
University Hospital Tuebingen · Sites in Germany
Ages 18–65
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 3
First in 2018; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 108 across the 28 interventional studies, 130 across the 13 observational. Of the 20 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 41 have an industry lead sponsor. The 10 most frequent:
Schön Klinik Berchtesgadener Land is the lead sponsor of 51 studies on the registry; 2 are open to participants now.
Schön Klinik Berchtesgadener Land has 3 studies filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Post-Acute COVID-19 Syndrome with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07197138Max-Planck-Institute of PsychiatryIMPACT-D+: Immune-Modulating and Psychometric Effects of Accelerated TMS in Depression Plus Comorbid Post-COVID-19 Condition | 2027-01 |
| NCT07110714Eggensberger OHGEffects of Kneipp Hydrotherapy in Post-COVID-19 Patients | 2027-01-31 |
| NCT07013903Schön Klinik Berchtesgadener LandEffects of Hydrotherapy During Post-COVID-19 Rehabilitation | 2027-01-31 |
| NCT06510985University Hospital TuebingenTranscutaneous Vagus Nerve Stimulation (tVNS) for Improved Recovery After Exertion. | 2027-05 |
| NCT05638724Technical University of MunichMunich Long COVID Registry for Children, Adolescents, and Adults | 2027-07-20 |
Add all 5 to your calendar (.ics) → With an account.
Among the 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled study evaluates the effects of cold water hydrotherapy as an adjunct to standard rehabilitation in patients with Post-COVID Syndrome. The primary aim is to assess changes in quality of life compared to standard rehabilitation alone.
Patients recovering from Post-COVID Syndrome often experience persistent fatigue, autonomic dysregulation, microcirculatory disturbances, and low-grade inflammation, all of which may hinder their return to full function. Kneipp hydrotherapy-using cold water applications-can address these pathophysiological changes through several mechanisms:
Autonomic regulation: Cold stimuli trigger parasympathetic activation and improve sympathovagal balance, helping to stabilize heart rate variability and reduce symptoms of dysautonomia often seen in Post-COVID.
Enhanced microcirculation: Repeated vasoconstriction and reactive vasodilation promote endothelial function and tissue perfusion, which may alleviate muscle aches, dizziness, and fatigue by improving oxygen and nutrient delivery.
Anti-inflammatory effects: Hydrothermal stimuli have been shown to modulate cytokine profiles, increasing anti-inflammatory mediators and potentially dampening the persistent, low-grade inflammation implicated in Post-COVID pathophysiology.
Musculoskeletal recovery: Thermo-mechanical stimulation relaxes tense muscle fibers, reduces pain perception, and supports gradual increases in physical capacity, all of which are important for overcoming Post-COVID deconditioning.
Taken together, these effects suggest that adjunctive cold water hydrotherapy could accelerate functional recovery, reduce symptom burden, and enhance quality of life in Post-COVID rehabilitation.
Baseline Assessments:
At baseline, demographic data including sex, age, height, and weight will be collected. Participants will report their current main Post-COVID symptoms, which will be categorized into symptom clusters: Fatigue (A), Cognitive (B), and Somatic (C). Smoking history will be assessed, including smoking status (current, former, or never), number of cigarettes per day, years of smoking, and pack-years.
The time (in months) since the COVID-19 infection that led to Post-COVID syndrome will be documented, along with the number of COVID-19 vaccinations received at the time of infection. Employment status will be recorded, distinguishing between full-time or part-time employment, COVID-related work disability, retirement, unemployment, or disability pension.
Comorbidities will be documented across the following categories: cardiovascular, pulmonary, cerebrovascular, metabolic, musculoskeletal, psychiatric, and other conditions. The severity of the acute COVID-19 illness will be assessed using the WHO Clinical Progression Scale, including information on any hospital admission and length of stay (in days).
Pulmonary function testing at baseline (V1) will include FEV₁, FVC, FEV₁/FVC ratio, and total lung capacity (TLC), all expressed as percent predicted. Autonomic function will be evaluated using the Schellong test. Vascular status will be assessed by four-limb blood pressure measurement. Additionally, self-reported work ability and the number of Post-COVID-related sick leave days within the past 12 weeks will be recorded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cold water hydrotherapy (5-10 minutes each), twice daily during the 3-week multimodal inpatient rehabilitation program and once daily during the 6-month follow-up period
Other: Standard rehabilitation plus cold water hydrotherapy
3-week inpatient multimodal inpatient rehabilitation program without hydrotherapy
Other: Standard rehabilitation only
Cold water hydrotherapy (5-10 minutes each), twice daily during the 3-week multimodal inpatient rehabilitation program and once daily during the 6-month follow-up period
same rehabilitation program than the experimental group but without hydrotherapy
Health-related quality of life by Short Form-12 Health Survey (SF-12)
Change in the Short Form-12 physical and mental component summary scores
Time frame: From baseline (Visit 1) to end of inpatient rehabilitation (3 weeks, Visit 2)
Fatigue severity by Fatigue Severity Scale
Change in Fatigue Severity Scale score
Time frame: From baseline (Visit 1) to end of inpatient rehabilitation (3 weeks, Visit 2)
Sleep quality by Pittsburgh Sleep Quality Index
Change in Pittsburgh Sleep Quality Index score
Time frame: From baseline (Visit 1) to end of inpatient rehabilitation (3 weeks, Visit 2)
Health status by EuroQol-5 Dimensions-5 Levels
Change in EuroQol-5 Dimensions-5 Levels questionnaire score
Time frame: From baseline (Visit 1) to end of inpatient rehabilitation (3 weeks, Visit 2)
Autonomic function (heart rate variability by photoplethysmography)
Change in heart rate variability (root mean square of successive differences) measured by Kyto 2935 via photoplethysmography
Time frame: Daily during first 3 weeks of rehabilitation (Visit 1 to Visit 2)
Resting blood pressure (systolic and diastolic)
Change in morning resting systolic and diastolic blood pressure
Time frame: Daily during first 3 weeks of rehabilitation (Visit 1 to Visit 2)
Post-COVID work-absence days
Number of days of work absence due to Post-COVID-19 symptoms during the past 12-weeks
Time frame: From baseline (Visit 1) to 3 months (Visit 3) and to 6 months (Visit 4)
Long-term quality of life by Short Form-12
Change in Short Form-12 scores at follow-up
Time frame: From baseline (Visit 1) to 3 months (Visit 3) and to 6 months (Visit 4)
Long-term fatigue by Fatigue Severity Scale
Change in Fatigue Severity Scale score at follow-up
Time frame: From baseline (Visit 1) to 3 months (Visit 3) and to 6 months (Visit 4)
Adherence to hydrotherapy
Proportion of prescribed hydrotherapy applications in the intervention group performed, as recorded in diary or app. Short-term Adherence: During the 3-week intervention phase, patients are considered "adherent" if they perform at least one hydrotherapy session per day on at least 75% of study days. We will compare health improvements between high-adherence and low-adherence participants. Long-term Adherence and Effects: Over the 3- and 6-month follow-up, "adherent" patients are those who continue self-administered hydrotherapy at least four times per week on at least 75% of follow-up weeks. We will assess whether these patients sustain greater gains in quality of life.
Time frame: During the 3-week intervention phase (up to Visit 2) and over the 6-month follow-up period (to Visit 4)
Adverse events recording
Number and severity of adverse events related to Kneipp hydrotherapy
Time frame: From start of intervention (Visit 1) through end of study (Visit 4, 6-month follow-up)
Long-term heart rate variability changes (HRV)
Change in heart rate variability parameters (root mean square of successive differences) measured by photoplethysmography. At follow-up visits patients will measure HRV for 7 consecutive days
Time frame: From baseline (Visit 1) to 3 months (Visit 3) and to 6 months (Visit 4)
Post-exertional malaise severity
Change in Post-Exertional Malaise score measured by the DePaul Symptom Questionnaire-Post-Exertional Malaise
Time frame: From baseline (Visit 1) to 6-month (Visit 4) follow-up
Daily well-being documentation
Self-reported daily well-being recorded via digital diary on a scale from 0 to 100
Time frame: Daily throughout the intervention and 6 months follow-up phase (Visit 1 to Visit 4)
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Jan 2027, 17 months after the start.
Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 17 months is close to that.
Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →
Schön Klinik Berchtesgadener Land